The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development
Editor's Choice

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development

DEC 1, 2021
Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology
Finance

Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology

NOV 30, 2021
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

NOV 23, 2021
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Clinical & Manufacturing

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

NOV 19, 2021
Engineering the Microbiome to Treat Skin Diseases
Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

NOV 16, 2021
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Clinical & Manufacturing

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

NOV 12, 2021
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

NOV 10, 2021
ADM to Acquire Deerland Probiotics & Enzymes
Biotics and Supplements

ADM to Acquire Deerland Probiotics & Enzymes

NOV 5, 2021
Probiotics : A Helping Hand Toward a Fitter Life
Biotics and Supplements

Probiotics : A Helping Hand Toward a Fitter Life

OCT 27, 2021
New study characterizes the gut virome
Pharma & Human Health

New study characterizes the gut virome

OCT 25, 2021
Solarea Bio Announces Licensing Agreement with ADM
Pharma & Human Health

Solarea Bio Announces Licensing Agreement with ADM

OCT 20, 2021